Barclays’s Transmedics TMDX Stock Holding History

Barclays’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-24,000	Closed	-$1.77M	–	5295
2024 Q1	$1.77M	Buy	+24,000	New	+$1.98M	﹤0.01%	2675

Other funds holding TMDX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Barclays's TMDX Position: Q1 2026 in Review

Barclays reduced its Transmedics (TMDX) stake by 4.6% in Q1 2026, selling an estimated $1.19M and leaving 190,578 shares worth $18.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1126.

Barclays first reported a position in TMDX in Q2 2019 and has held it in 28 quarters since. The position peaked at $30M in Q3 2024. 414 funds tracked by Wall St. Rank hold TMDX as of Q1 2026.

Barclays held 190,578 shares of Transmedics worth $18.9M as of Q1 2026.
Barclays sold 9,127 Transmedics shares in Q1 2026, an estimated $1.19M.
Transmedics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #1126 holding.
Barclays first reported a position in Transmedics in Q2 2019 and has held it in 28 quarters since.
Barclays's Transmedics position peaked at $30M in Q3 2024.
414 funds tracked by Wall St. Rank held Transmedics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.